These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 39332796)

  • 1. Cardiovascular effects of Roflumilast during sepsis: Risks or benefits?
    Ferreira Alves G; Oliveira JG; Nakashima MA; Delfrate G; Sordi R; Assreuy J; da Silva-Santos JE; Collino M; Fernandes D
    Eur J Pharmacol; 2024 Nov; 983():177015. PubMed ID: 39332796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphodiestrase-1 and 4 inhibitors ameliorate liver fibrosis in rats: Modulation of cAMP/CREB/TLR4 inflammatory and fibrogenic pathways.
    Essam RM; Ahmed LA; Abdelsalam RM; El-Khatib AS
    Life Sci; 2019 Apr; 222():245-254. PubMed ID: 30858122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphodiesterase-4 inhibition as a therapeutic approach to treat capillary leakage in systemic inflammation.
    Schick MA; Wunder C; Wollborn J; Roewer N; Waschke J; Germer CT; Schlegel N
    J Physiol; 2012 Jun; 590(11):2693-708. PubMed ID: 22495586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roflumilast, a Phosphodiesterases-4 (PDE4) Inhibitor, Alleviates Sepsis‑induced Acute Kidney Injury.
    Xu X; Liao L; Hu B; Jiang H; Tan M
    Med Sci Monit; 2020 May; 26():e921319. PubMed ID: 32449901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of tadalafil (PDE5 inhibitor) and roflumilast (PDE4 inhibitor) on airway reactivity and markers of inflammation in ovalbumin-induced airway hyperresponsiveness in guinea pigs.
    Mokry J; Urbanova A; Medvedova I; Kertys M; Mikolka P; Kosutova P; Mokra D
    J Physiol Pharmacol; 2017 Oct; 68(5):721-730. PubMed ID: 29375047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roflumilast counteracts DMH-induced preneoplastic colon damage in albino Wistar rats.
    Saeedan AS; Rastogi S; Ansari MN
    Hum Exp Toxicol; 2020 Nov; 39(11):1545-1555. PubMed ID: 32524861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PDE4 inhibitor, roflumilast protects cardiomyocytes against NO-induced apoptosis via activation of PKA and Epac dual pathways.
    Kwak HJ; Park KM; Choi HE; Chung KS; Lim HJ; Park HY
    Cell Signal; 2008 May; 20(5):803-14. PubMed ID: 18276108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Roflumilast, type 4 phosphodiesterase inhibitor, attenuates inflammation in rats with ulcerative colitis via down-regulation of iNOS and elevation of cAMP.
    El-Ashmawy NE; Khedr NF; El-Bahrawy HA; El-Adawy SA
    Int Immunopharmacol; 2018 Mar; 56():36-42. PubMed ID: 29331766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The glucose-lowering effects of the PDE4 inhibitors roflumilast and roflumilast-N-oxide in db/db mice.
    Vollert S; Kaessner N; Heuser A; Hanauer G; Dieckmann A; Knaack D; Kley HP; Beume R; Weiss-Haljiti C
    Diabetologia; 2012 Oct; 55(10):2779-2788. PubMed ID: 22790061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roflumilast reverses polymicrobial sepsis-induced liver damage by inhibiting inflammation in mice.
    Feng H; Chen J; Wang H; Cheng Y; Zou Z; Zhong Q; Xu J
    Lab Invest; 2017 Sep; 97(9):1008-1019. PubMed ID: 28650427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Roflumilast, a phosphodiesterase-4 inhibitor, improves hyperoxia-induced lung injury via anti-inflammation.
    Cao HY; Yu TH; Han CH; Liu WW; Zhang PX; Tang P
    Undersea Hyperb Med; 2020; 47(2):189-196. PubMed ID: 32574434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Roflumilast and tadalafil improve learning and memory deficits in intracerebroventricular Aβ1-42 rat model of Alzheimer's disease through modulations of hippocampal cAMP/cGMP/BDNF signaling pathway.
    Hasan N; Zameer S; Najmi AK; Parvez S; Yar MS; Akhtar M
    Pharmacol Rep; 2021 Oct; 73(5):1287-1302. PubMed ID: 33860460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease.
    Rabe KF
    Br J Pharmacol; 2011 May; 163(1):53-67. PubMed ID: 21232047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PDE4 inhibition reduces neointima formation and inhibits VCAM-1 expression and histone methylation in an Epac-dependent manner.
    Lehrke M; Kahles F; Makowska A; Tilstam PV; Diebold S; Marx J; Stöhr R; Hess K; Endorf EB; Bruemmer D; Marx N; Findeisen HM
    J Mol Cell Cardiol; 2015 Apr; 81():23-33. PubMed ID: 25640159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of phosphodiesterase IV enzyme improves locomotor and sensory complications of spinal cord injury via altering microglial activity: Introduction of Roflumilast as an alternative therapy.
    Moradi K; Golbakhsh M; Haghighi F; Afshari K; Nikbakhsh R; Khavandi MM; Faghani S; Badripour A; Etemadi A; Ashraf-Ganjouei A; Bagheri S; Dehpour AR
    Int Immunopharmacol; 2020 Sep; 86():106743. PubMed ID: 32619958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of roflumilast, a phosphodiesterase-4 inhibitor, on hypoxia- and monocrotaline-induced pulmonary hypertension in rats.
    Izikki M; Raffestin B; Klar J; Hatzelmann A; Marx D; Tenor H; Zadigue P; Adnot S; Eddahibi S
    J Pharmacol Exp Ther; 2009 Jul; 330(1):54-62. PubMed ID: 19386793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roflumilast improves resolution of sepsis-induced acute kidney injury by retarding late phase renal interstitial immune cells infiltration and leakage in urinary sediments.
    Gupta K; Pandey S; Singh R; Kumari A; Sen P; Singh G
    Fundam Clin Pharmacol; 2022 Feb; 36(1):114-132. PubMed ID: 34212425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease.
    Cazzola M; Calzetta L; Rogliani P; Matera MG
    Expert Opin Drug Discov; 2016 Jul; 11(7):733-44. PubMed ID: 27169612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose dependent effects of tadalafil and roflumilast on ovalbumin-induced airway hyperresponsiveness in guinea pigs.
    Urbanova A; Medvedova I; Kertys M; Mikolka P; Kosutova P; Mokra D; Mokrý J
    Exp Lung Res; 2017; 43(9-10):407-416. PubMed ID: 29220595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
    Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H
    Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.